Breach of Contract Lawsuit | Mergers & Acquisitions | Business

1. Introduction

On October 31, 2025, Pfizer filed a complaint in the Delaware Court of Chancery against Metsera, Metsera’s Board of Directors, and Novo Nordisk. The lawsuit alleges breach of contract, breach of fiduciary duty, and tortious interference in connection with the merger agreement between Pfizer and Metsera. (Investing.com South Africa)

At its core: Pfizer claims that Metsera and Novo Nordisk are violating the merger agreement by treating Novo’s unsolicited bid as a “superior proposal” and attempting to terminate or divert the Pfizer transaction—despite Pfizer having met regulatory conditions and being ready to close. (Reuters)

This dispute is more than boardroom drama, it highlights issues of contract enforcement in M&A, fiduciary duties in target boards, regulatory risk in pharma deals, and the increasingly aggressive posture of bidders defending their agreements.

2. Background & Deal Sequence

2.1 The Pfizer-Metsera Agreement

In September 2025, Metsera and Pfizer entered into a definitive Agreement and Plan of Merger under which Merger Sub, a subsidiary of Pfizer, would merge into Metsera, with Metsera surviving as a wholly-owned subsidiary of Pfizer. The transaction consideration was approximately US $4.9 billion (cash + contingent value rights) according to earlier disclosures. (Johnson Fistel)

As part of that merger agreement, Metsera’s board made certain representations, and included “no‐solicitation” and “matching rights” clauses typical in deal contracts (i.e., if a superior offer arrives, the target must follow processes, and the original buyer may have rights to match).

2.2 The Novo Nordisk Bid & Triggering of Dispute

On or about October 25, 2025, Novo Nordisk made an unsolicited proposal for Metsera valued at up to approximately US $9 billion. Metsera’s board declared this proposal a “Superior Company Proposal” under the merger agreement with Pfizer. (Stock Titan)

Pfizer contests that Novo’s bid cannot be a “superior” proposal because, in its words, it is “not reasonably likely to be completed on the terms proposed in light of the significant regulatory risk.” (Investing.com South Africa) Pfizer also criticises the structure of Novo’s bid as designed to “evade antitrust review” and as an “illegal attempt by a company with a dominant market position to suppress competition.” (Investing.com South Africa)

Upon that declaration, the merger agreement would have triggered Pfizer’s matching rights (or other rights) and potentially a required counteroffer or termination fee scenario. Pfizer’s lawsuit seeks to prevent Metsera from terminating the Pfizer agreement or entering into the Novo deal.

3. Key Legal Issues in the Lawsuit

3.1 Contractual Obligations & Matching Rights

The dispute centres on the meaning and enforceability of the “superior proposal” clause in the merger agreement. Key questions:

• What constitutes a “superior” proposal in quantitative and qualitative terms?
• Does regulatory risk (or reasonable likelihood of closing) factor into the target board’s evaluation of superiority?
• Is the target board obligated to act in favour of the original acquirer if the matching rights are triggered?

Pfizer asserts that Metsera’s board breached its contractual duties by accepting Novo’s proposal without giving Pfizer full opportunity—or by way of structuring the alternate deal in a way to avoid regulatory scrutiny, contrary to the spirit of the agreement.

3.2 Fiduciary Duties of the Target Board

In Delaware law, the board of a target company has fiduciary duties (care, loyalty) when evaluating bids and processing change of control transactions. The board must act in the best interests of shareholders, including obtaining fair price and proper process.

Pfizer’s complaint alleges that Metsera’s board breached its fiduciary duties by favouring Novo’s bid and entering into indemnification/structure arrangements beneficial to directors (including self-dealing or conflicted decisionmaking) and by failing to act in the best interests of shareholders or Pfizer as contracting party. (Investing.com South Africa)

3.3 Tortious Interference & Antitrust/Risk Considerations

Pfizer also alleges that Novo Nordisk tortiously interfered with the merger agreement by inducing Metsera’s board to terminate or divert the agreement, notwithstanding the contractual rights granted to Pfizer. Pfizer further argues regulatory risk (antitrust and foreign-investment scrutiny) renders Novo’s bid less likely to close and thus not truly “superior.”

There is an added layer: Pfizer frames the dispute in competitive terms—arguing that Novo, a dominant player in the obesity/weight-loss drug market, is attempting to acquire Metsera (a company in the obesity drug pipeline) to suppress competition. This brings regulatory/antitrust overtones to what might otherwise be a pure contract dispute.

3.4 Enforceability of Injunctive Relief & Specific Performance

Pfizer is seeking injunctive relief (including a temporary restraining order) to prevent Metsera from terminating the agreement or proceeding with the alternative deal while the court adjudicates the rights. Whether a court grants specific performance (i.e., force the deal to close) or only damages will be a key practical matter.

4. Strategic & Market Implications

4.1 M&A Precedent in Pharma

The pharmaceutical industry is intensely competitive, especially in emerging markets like obesity drugs and cardiometabolic disease treatments. This dispute underscores the importance of securing regulatory clearances, controlling deal structure risk, and drafting robust merger agreements that anticipate topping bids and regulatory snapshots.

4.2 Domestic vs. Foreign Bidders & Political Dimensions

Pfizer emphasises its U.S. identity and casts Novo’s bid (a Danish company) in terms of foreign competition and regulatory risk (mentioning Committee on Foreign Investment in the U.S. (CFIUS) scrutiny). (Reuters) Such framing may resonate in political/regulatory arenas and suggests that bidders will increasingly align deal strategy with national-security or antitrust narratives.

4.3 Price & Structure of Bids

The Novo bid reportedly used a two-step structure (cash + preferred shares + contingent value rights), which Pfizer claims is designed to evade regulatory risk or antitrust review. Structural innovations of this kind will become more common, and original bidders must anticipate how such structures may trigger or avoid contractual thresholds (e.g., “superior” definitions).

4.4 Shareholder Relations & Break-Fee Risk

Target shareholders may object if boards accept bids that deliver less value, or if they favour one bidder over another without transparent process. Also, if a deal is terminated or diverted, break-fees and damage awards may accrue. The lawsuit spotlight may slow down other deals or raise deal‐risk premiums.

5. What to Watch Going Forward

• Will the court grant a temporary restraining order or injunction preventing Metsera’s board from proceeding with the Novo bid?
• How will the court interpret “reasonably likely to be completed” in the contract context (i.e., factoring regulatory risks)?
• Will the target shareholders push back against the board or seek appraisal rights if the deal goes through?
• How will regulatory agencies (FTC, CFIUS) respond given the competitive and foreign bidder dimensions?
• Could this case influence how future merger agreements define “superior proposal,” regulatory-risk carve-outs and matching rights?

6. Conclusion

The Pfizer–Metsera conflict is more than a bidding war—it is a test of how seriously companies enforce merger agreements, the duties of target boards in fast-moving sectors, and how regulatory risk and competition theory intersect with contract law. For bidders, targets, counsel, and regulators, this dispute sends a clear message: merger agreements matter, and the structure, process and regulatory path are as important as price.

Pfizer has chosen litigation to defend its contractual rights rather than simply increase its bid or walk away. Whether that gamble succeeds will shape not only which company controls Metsera’s pipeline—but how future deals are drafted, challenged, and litigated.